CN116832105B - Traditional Chinese medicine preparation for protecting kidney and promoting urination and preparation method thereof - Google Patents
Traditional Chinese medicine preparation for protecting kidney and promoting urination and preparation method thereof Download PDFInfo
- Publication number
- CN116832105B CN116832105B CN202310900192.0A CN202310900192A CN116832105B CN 116832105 B CN116832105 B CN 116832105B CN 202310900192 A CN202310900192 A CN 202310900192A CN 116832105 B CN116832105 B CN 116832105B
- Authority
- CN
- China
- Prior art keywords
- kidney
- protecting
- diuretic
- traditional chinese
- chinese medicine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000003814 drug Substances 0.000 title claims abstract description 112
- 238000002360 preparation method Methods 0.000 title claims abstract description 84
- 210000003734 kidney Anatomy 0.000 title claims abstract description 52
- 230000001737 promoting effect Effects 0.000 title claims abstract description 41
- 230000027939 micturition Effects 0.000 title claims abstract description 20
- 229940079593 drug Drugs 0.000 claims abstract description 44
- 239000002934 diuretic Substances 0.000 claims abstract description 33
- 230000001882 diuretic effect Effects 0.000 claims abstract description 33
- 241000222640 Polyporus Species 0.000 claims abstract description 16
- 239000002994 raw material Substances 0.000 claims abstract description 4
- 239000000203 mixture Substances 0.000 claims description 38
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 38
- 239000000706 filtrate Substances 0.000 claims description 37
- 238000001914 filtration Methods 0.000 claims description 18
- 238000002156 mixing Methods 0.000 claims description 18
- 241000209035 Ilex Species 0.000 claims description 11
- 235000003332 Ilex aquifolium Nutrition 0.000 claims description 9
- 235000002296 Ilex sandwicensis Nutrition 0.000 claims description 9
- 235000002294 Ilex volkensiana Nutrition 0.000 claims description 9
- 235000006200 Glycyrrhiza glabra Nutrition 0.000 claims description 8
- 244000303040 Glycyrrhiza glabra Species 0.000 claims description 8
- 241001116757 Pyrrosia lingua Species 0.000 claims description 8
- 238000000034 method Methods 0.000 claims description 7
- 241000722953 Akebia Species 0.000 claims description 5
- 240000007164 Salvia officinalis Species 0.000 claims description 5
- LPLVUJXQOOQHMX-QWBHMCJMSA-N glycyrrhizinic acid Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-N 0.000 claims description 5
- 235000011477 liquorice Nutrition 0.000 claims description 5
- 235000005412 red sage Nutrition 0.000 claims description 5
- 240000009215 Nepeta cataria Species 0.000 claims description 3
- 235000010679 Nepeta cataria Nutrition 0.000 claims description 3
- ZDKZHVNKFOXMND-UHFFFAOYSA-N epinepetalactone Chemical compound O=C1OC=C(C)C2C1C(C)CC2 ZDKZHVNKFOXMND-UHFFFAOYSA-N 0.000 claims description 3
- 239000000463 material Substances 0.000 claims description 3
- 239000002775 capsule Substances 0.000 claims description 2
- 239000008187 granular material Substances 0.000 claims description 2
- 239000006187 pill Substances 0.000 claims description 2
- 230000000694 effects Effects 0.000 abstract description 25
- 241000287828 Gallus gallus Species 0.000 abstract description 23
- 208000004880 Polyuria Diseases 0.000 abstract description 20
- 230000035619 diuresis Effects 0.000 abstract description 20
- 208000015181 infectious disease Diseases 0.000 abstract description 14
- 230000002458 infectious effect Effects 0.000 abstract description 12
- 206010006451 bronchitis Diseases 0.000 abstract description 11
- 239000002671 adjuvant Substances 0.000 abstract description 5
- 206010025421 Macule Diseases 0.000 abstract 1
- 238000012360 testing method Methods 0.000 description 27
- 235000013330 chicken meat Nutrition 0.000 description 22
- 241000700159 Rattus Species 0.000 description 21
- 210000004369 blood Anatomy 0.000 description 16
- 239000008280 blood Substances 0.000 description 16
- 208000002193 Pain Diseases 0.000 description 13
- 230000036407 pain Effects 0.000 description 13
- 208000024891 symptom Diseases 0.000 description 12
- LEHOTFFKMJEONL-UHFFFAOYSA-N Uric Acid Chemical compound N1C(=O)NC(=O)C2=C1NC(=O)N2 LEHOTFFKMJEONL-UHFFFAOYSA-N 0.000 description 11
- 210000002784 stomach Anatomy 0.000 description 10
- 230000000052 comparative effect Effects 0.000 description 9
- 102000012422 Collagen Type I Human genes 0.000 description 8
- 108010022452 Collagen Type I Proteins 0.000 description 8
- GFFGJBXGBJISGV-UHFFFAOYSA-N Adenine Chemical compound NC1=NC=NC2=C1N=CN2 GFFGJBXGBJISGV-UHFFFAOYSA-N 0.000 description 7
- 229930024421 Adenine Natural products 0.000 description 7
- 229960000643 adenine Drugs 0.000 description 7
- 230000001939 inductive effect Effects 0.000 description 7
- 206010030113 Oedema Diseases 0.000 description 6
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 6
- 230000017531 blood circulation Effects 0.000 description 6
- 238000002474 experimental method Methods 0.000 description 6
- 210000002216 heart Anatomy 0.000 description 6
- 210000001124 body fluid Anatomy 0.000 description 5
- 239000010839 body fluid Substances 0.000 description 5
- 230000003203 everyday effect Effects 0.000 description 5
- 210000004072 lung Anatomy 0.000 description 5
- 210000002460 smooth muscle Anatomy 0.000 description 5
- 229940116269 uric acid Drugs 0.000 description 5
- 229940126673 western medicines Drugs 0.000 description 5
- 206010012735 Diarrhoea Diseases 0.000 description 4
- 102000004887 Transforming Growth Factor beta Human genes 0.000 description 4
- 108090001012 Transforming Growth Factor beta Proteins 0.000 description 4
- TVWHNULVHGKJHS-UHFFFAOYSA-N Uric acid Natural products N1C(=O)NC(=O)C2NC(=O)NC21 TVWHNULVHGKJHS-UHFFFAOYSA-N 0.000 description 4
- 230000003213 activating effect Effects 0.000 description 4
- 235000021053 average weight gain Nutrition 0.000 description 4
- 235000019658 bitter taste Nutrition 0.000 description 4
- 208000020832 chronic kidney disease Diseases 0.000 description 4
- 208000022831 chronic renal failure syndrome Diseases 0.000 description 4
- 230000004087 circulation Effects 0.000 description 4
- 230000002354 daily effect Effects 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 230000006870 function Effects 0.000 description 4
- 238000000465 moulding Methods 0.000 description 4
- 230000008961 swelling Effects 0.000 description 4
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 description 4
- 210000005239 tubule Anatomy 0.000 description 4
- 238000011144 upstream manufacturing Methods 0.000 description 4
- 206010011224 Cough Diseases 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- 208000001647 Renal Insufficiency Diseases 0.000 description 3
- 102000046299 Transforming Growth Factor beta1 Human genes 0.000 description 3
- 101800002279 Transforming growth factor beta-1 Proteins 0.000 description 3
- 230000001488 breeding effect Effects 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 235000009508 confectionery Nutrition 0.000 description 3
- 238000001816 cooling Methods 0.000 description 3
- 239000013078 crystal Substances 0.000 description 3
- 210000003608 fece Anatomy 0.000 description 3
- 230000001976 improved effect Effects 0.000 description 3
- 230000001965 increasing effect Effects 0.000 description 3
- 201000006370 kidney failure Diseases 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 235000017557 sodium bicarbonate Nutrition 0.000 description 3
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 3
- 235000019605 sweet taste sensations Nutrition 0.000 description 3
- 210000004926 tubular epithelial cell Anatomy 0.000 description 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 2
- XFBOJHLYDJZYSP-UHFFFAOYSA-N 2,8-dioxoadenine Chemical compound N1C(=O)N=C2NC(=O)NC2=C1N XFBOJHLYDJZYSP-UHFFFAOYSA-N 0.000 description 2
- WZUODJNEIXSNEU-UHFFFAOYSA-N 2-Hydroxy-4-methoxybenzaldehyde Chemical compound COC1=CC=C(C=O)C(O)=C1 WZUODJNEIXSNEU-UHFFFAOYSA-N 0.000 description 2
- -1 2-hydroxy-alpha-hydroxy-tetracosanol Chemical compound 0.000 description 2
- IBGBGRVKPALMCQ-UHFFFAOYSA-N 3,4-dihydroxybenzaldehyde Chemical compound OC1=CC=C(C=O)C=C1O IBGBGRVKPALMCQ-UHFFFAOYSA-N 0.000 description 2
- YQUVCSBJEUQKSH-UHFFFAOYSA-N 3,4-dihydroxybenzoic acid Chemical compound OC(=O)C1=CC=C(O)C(O)=C1 YQUVCSBJEUQKSH-UHFFFAOYSA-N 0.000 description 2
- 102000007469 Actins Human genes 0.000 description 2
- 108010085238 Actins Proteins 0.000 description 2
- 240000008027 Akebia quinata Species 0.000 description 2
- 235000007756 Akebia quinata Nutrition 0.000 description 2
- 244000080767 Areca catechu Species 0.000 description 2
- 241000903946 Clematidis Species 0.000 description 2
- 241000721047 Danaus plexippus Species 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 2
- 235000017443 Hedysarum boreale Nutrition 0.000 description 2
- 235000007858 Hedysarum occidentale Nutrition 0.000 description 2
- 241000711450 Infectious bronchitis virus Species 0.000 description 2
- 206010023421 Kidney fibrosis Diseases 0.000 description 2
- 241000207923 Lamiaceae Species 0.000 description 2
- 206010068319 Oropharyngeal pain Diseases 0.000 description 2
- 201000007100 Pharyngitis Diseases 0.000 description 2
- 244000171085 Polyporus umbellatus Species 0.000 description 2
- 235000004837 Polyporus umbellatus Nutrition 0.000 description 2
- 208000001431 Psychomotor Agitation Diseases 0.000 description 2
- 206010038743 Restlessness Diseases 0.000 description 2
- 241000700605 Viruses Species 0.000 description 2
- 238000009825 accumulation Methods 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 230000001154 acute effect Effects 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 230000036528 appetite Effects 0.000 description 2
- 235000019789 appetite Nutrition 0.000 description 2
- 238000009395 breeding Methods 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 description 2
- 238000007599 discharging Methods 0.000 description 2
- 210000000981 epithelium Anatomy 0.000 description 2
- 230000029142 excretion Effects 0.000 description 2
- 239000001947 glycyrrhiza glabra rhizome/root Substances 0.000 description 2
- 241000411851 herbal medicine Species 0.000 description 2
- VKYKSIONXSXAKP-UHFFFAOYSA-N hexamethylenetetramine Chemical compound C1N(C2)CN3CN1CN2C3 VKYKSIONXSXAKP-UHFFFAOYSA-N 0.000 description 2
- 230000036039 immunity Effects 0.000 description 2
- 208000017169 kidney disease Diseases 0.000 description 2
- 210000000738 kidney tubule Anatomy 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 239000003550 marker Substances 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 230000001717 pathogenic effect Effects 0.000 description 2
- 230000036285 pathological change Effects 0.000 description 2
- 231100000915 pathological change Toxicity 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 210000005084 renal tissue Anatomy 0.000 description 2
- 230000000241 respiratory effect Effects 0.000 description 2
- 210000000813 small intestine Anatomy 0.000 description 2
- 210000000952 spleen Anatomy 0.000 description 2
- 235000019640 taste Nutrition 0.000 description 2
- 239000003053 toxin Substances 0.000 description 2
- 231100000765 toxin Toxicity 0.000 description 2
- 229940099456 transforming growth factor beta 1 Drugs 0.000 description 2
- 210000000626 ureter Anatomy 0.000 description 2
- 238000012795 verification Methods 0.000 description 2
- OILXMJHPFNGGTO-UHFFFAOYSA-N (22E)-(24xi)-24-methylcholesta-5,22-dien-3beta-ol Natural products C1C=C2CC(O)CCC2(C)C2C1C1CCC(C(C)C=CC(C)C(C)C)C1(C)CC2 OILXMJHPFNGGTO-UHFFFAOYSA-N 0.000 description 1
- RQOCXCFLRBRBCS-UHFFFAOYSA-N (22E)-cholesta-5,7,22-trien-3beta-ol Natural products C1C(O)CCC2(C)C(CCC3(C(C(C)C=CCC(C)C)CCC33)C)C3=CC=C21 RQOCXCFLRBRBCS-UHFFFAOYSA-N 0.000 description 1
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 1
- KWBPKUMWVXUSCA-AXQDKOMKSA-N 3-[(3s,5s,8r,9s,10r,13r,14s,17r)-5,14-dihydroxy-3-[(2r,4s,5r,6r)-4-methoxy-6-methyl-5-[(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxan-2-yl]oxy-10,13-dimethyl-2,3,4,6,7,8,9,11,12,15,16,17-dodecahydro-1h-cyclopenta[a]phenanthren-17-yl] Chemical compound C1([C@@H]2[C@@]3(C)CC[C@@H]4[C@@]5(C)CC[C@@H](C[C@@]5(O)CC[C@H]4[C@@]3(O)CC2)O[C@H]2C[C@@H]([C@@H]([C@@H](C)O2)O[C@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)O)OC)=CC(=O)OC1 KWBPKUMWVXUSCA-AXQDKOMKSA-N 0.000 description 1
- ZTKDMNHEQMILPE-UHFFFAOYSA-N 4-methoxy-n,n-dimethylaniline Chemical compound COC1=CC=C(N(C)C)C=C1 ZTKDMNHEQMILPE-UHFFFAOYSA-N 0.000 description 1
- OQMZNAMGEHIHNN-UHFFFAOYSA-N 7-Dehydrostigmasterol Natural products C1C(O)CCC2(C)C(CCC3(C(C(C)C=CC(CC)C(C)C)CCC33)C)C3=CC=C21 OQMZNAMGEHIHNN-UHFFFAOYSA-N 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 241000208327 Apocynaceae Species 0.000 description 1
- 235000006226 Areca catechu Nutrition 0.000 description 1
- 208000006820 Arthralgia Diseases 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- QFOHBWFCKVYLES-UHFFFAOYSA-N Butylparaben Chemical compound CCCCOC(=O)C1=CC=C(O)C=C1 QFOHBWFCKVYLES-UHFFFAOYSA-N 0.000 description 1
- 241000345998 Calamus manan Species 0.000 description 1
- 240000006620 Calla palustris Species 0.000 description 1
- 235000004012 Calla palustris Nutrition 0.000 description 1
- 241000717675 Clerodendranthus Species 0.000 description 1
- 235000019750 Crude protein Nutrition 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 208000020401 Depressive disease Diseases 0.000 description 1
- 208000000059 Dyspnea Diseases 0.000 description 1
- 206010013975 Dyspnoeas Diseases 0.000 description 1
- DNVPQKQSNYMLRS-NXVQYWJNSA-N Ergosterol Natural products CC(C)[C@@H](C)C=C[C@H](C)[C@H]1CC[C@H]2C3=CC=C4C[C@@H](O)CC[C@]4(C)[C@@H]3CC[C@]12C DNVPQKQSNYMLRS-NXVQYWJNSA-N 0.000 description 1
- 241000220485 Fabaceae Species 0.000 description 1
- 206010016654 Fibrosis Diseases 0.000 description 1
- 206010017553 Furuncle Diseases 0.000 description 1
- 206010018612 Gonorrhoea Diseases 0.000 description 1
- 206010018852 Haematoma Diseases 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 206010019345 Heat stroke Diseases 0.000 description 1
- 208000032843 Hemorrhage Diseases 0.000 description 1
- 235000003325 Ilex Nutrition 0.000 description 1
- 206010062717 Increased upper airway secretion Diseases 0.000 description 1
- 241000483399 Ipimorpha retusa Species 0.000 description 1
- 241000731961 Juncaceae Species 0.000 description 1
- 208000001705 Mouth breathing Diseases 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 206010029164 Nephrotic syndrome Diseases 0.000 description 1
- 206010030302 Oliguria Diseases 0.000 description 1
- 206010033557 Palpitations Diseases 0.000 description 1
- 241001406327 Periploca sepium Species 0.000 description 1
- 201000005702 Pertussis Diseases 0.000 description 1
- 240000008154 Piper betle Species 0.000 description 1
- 235000008180 Piper betle Nutrition 0.000 description 1
- 241000222341 Polyporaceae Species 0.000 description 1
- 241000025505 Pyrrosia Species 0.000 description 1
- 241001558929 Sclerotium <basidiomycota> Species 0.000 description 1
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 1
- 208000005392 Spasm Diseases 0.000 description 1
- 208000007180 Sunstroke Diseases 0.000 description 1
- 206010042674 Swelling Diseases 0.000 description 1
- GAMYVSCDDLXAQW-AOIWZFSPSA-N Thermopsosid Natural products O(C)c1c(O)ccc(C=2Oc3c(c(O)cc(O[C@H]4[C@H](O)[C@@H](O)[C@H](O)[C@H](CO)O4)c3)C(=O)C=2)c1 GAMYVSCDDLXAQW-AOIWZFSPSA-N 0.000 description 1
- 241000219793 Trifolium Species 0.000 description 1
- UHWVSEOVJBQKBE-UHFFFAOYSA-N Trimetazidine Chemical compound COC1=C(OC)C(OC)=CC=C1CN1CCNCC1 UHWVSEOVJBQKBE-UHFFFAOYSA-N 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- 241001192934 Wilsoniana Species 0.000 description 1
- PNNCWTXUWKENPE-UHFFFAOYSA-N [N].NC(N)=O Chemical compound [N].NC(N)=O PNNCWTXUWKENPE-UHFFFAOYSA-N 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 150000001299 aldehydes Chemical class 0.000 description 1
- 230000003355 alkalizing urine Effects 0.000 description 1
- 229930013930 alkaloid Natural products 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 208000022531 anorexia Diseases 0.000 description 1
- 210000000702 aorta abdominal Anatomy 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 210000001142 back Anatomy 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 210000000601 blood cell Anatomy 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 229940097217 cardiac glycoside Drugs 0.000 description 1
- 239000002368 cardiac glycoside Substances 0.000 description 1
- 210000000845 cartilage Anatomy 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 229940109239 creatinine Drugs 0.000 description 1
- 210000000805 cytoplasm Anatomy 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 206010061428 decreased appetite Diseases 0.000 description 1
- 230000007850 degeneration Effects 0.000 description 1
- 230000018044 dehydration Effects 0.000 description 1
- 238000006297 dehydration reaction Methods 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 208000028659 discharge Diseases 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 208000002173 dizziness Diseases 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- DNVPQKQSNYMLRS-SOWFXMKYSA-N ergosterol Chemical compound C1[C@@H](O)CC[C@]2(C)[C@H](CC[C@]3([C@H]([C@H](C)/C=C/[C@@H](C)C(C)C)CC[C@H]33)C)C3=CC=C21 DNVPQKQSNYMLRS-SOWFXMKYSA-N 0.000 description 1
- 210000003414 extremity Anatomy 0.000 description 1
- 210000003746 feather Anatomy 0.000 description 1
- 235000021050 feed intake Nutrition 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 230000004761 fibrosis Effects 0.000 description 1
- 229930003944 flavone Natural products 0.000 description 1
- 150000002212 flavone derivatives Chemical class 0.000 description 1
- 235000011949 flavones Nutrition 0.000 description 1
- 229930003935 flavonoid Natural products 0.000 description 1
- 150000002215 flavonoids Chemical class 0.000 description 1
- 235000017173 flavonoids Nutrition 0.000 description 1
- 239000007850 fluorescent dye Substances 0.000 description 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
- 229930182478 glucoside Natural products 0.000 description 1
- 150000008131 glucosides Chemical class 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 229930182470 glycoside Natural products 0.000 description 1
- 150000002338 glycosides Chemical class 0.000 description 1
- 208000001786 gonorrhea Diseases 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 208000014617 hemorrhoid Diseases 0.000 description 1
- 206010020718 hyperplasia Diseases 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 206010022437 insomnia Diseases 0.000 description 1
- 210000002570 interstitial cell Anatomy 0.000 description 1
- 210000000281 joint capsule Anatomy 0.000 description 1
- 210000003127 knee Anatomy 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 210000002429 large intestine Anatomy 0.000 description 1
- 210000005229 liver cell Anatomy 0.000 description 1
- 210000003141 lower extremity Anatomy 0.000 description 1
- 201000003453 lung abscess Diseases 0.000 description 1
- 210000002751 lymph Anatomy 0.000 description 1
- 235000020068 maotai Nutrition 0.000 description 1
- 201000003102 mental depression Diseases 0.000 description 1
- 230000006996 mental state Effects 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- 210000003470 mitochondria Anatomy 0.000 description 1
- 210000005087 mononuclear cell Anatomy 0.000 description 1
- 201000009240 nasopharyngitis Diseases 0.000 description 1
- 201000008383 nephritis Diseases 0.000 description 1
- 208000009928 nephrosis Diseases 0.000 description 1
- 231100001027 nephrosis Toxicity 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- LPMXVESGRSUGHW-HBYQJFLCSA-N ouabain Chemical compound O[C@@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@H]1O[C@@H]1C[C@@]2(O)CC[C@H]3[C@@]4(O)CC[C@H](C=5COC(=O)C=5)[C@@]4(C)C[C@@H](O)[C@@H]3[C@@]2(CO)[C@H](O)C1 LPMXVESGRSUGHW-HBYQJFLCSA-N 0.000 description 1
- 235000011837 pasties Nutrition 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- LMZSCLAHNSQLBW-UHFFFAOYSA-N periplocin Natural products COC1CC(OC2CCC3(C)C(CCC4C3CCC5(C)C(CCC45C)C6=CC(=O)OC6)C2)OC(C)C1OC7OC(CO)C(O)C(O)C7O LMZSCLAHNSQLBW-UHFFFAOYSA-N 0.000 description 1
- 208000026435 phlegm Diseases 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 206010036067 polydipsia Diseases 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 244000144977 poultry Species 0.000 description 1
- 235000013594 poultry meat Nutrition 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 235000018102 proteins Nutrition 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 229960003371 protocatechualdehyde Drugs 0.000 description 1
- 230000001047 pyretic effect Effects 0.000 description 1
- 238000004445 quantitative analysis Methods 0.000 description 1
- 238000010791 quenching Methods 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 238000011552 rat model Methods 0.000 description 1
- 235000012950 rattan cane Nutrition 0.000 description 1
- 238000003753 real-time PCR Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 201000002793 renal fibrosis Diseases 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 208000023504 respiratory system disease Diseases 0.000 description 1
- 238000010839 reverse transcription Methods 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 239000000344 soap Substances 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 229930002534 steroid glycoside Natural products 0.000 description 1
- 238000005728 strengthening Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 230000001502 supplementing effect Effects 0.000 description 1
- 235000018553 tannin Nutrition 0.000 description 1
- 229920001864 tannin Polymers 0.000 description 1
- 239000001648 tannin Substances 0.000 description 1
- 210000002435 tendon Anatomy 0.000 description 1
- 230000008719 thickening Effects 0.000 description 1
- 230000035922 thirst Effects 0.000 description 1
- 231100000167 toxic agent Toxicity 0.000 description 1
- 239000003440 toxic substance Substances 0.000 description 1
- 229940126680 traditional chinese medicines Drugs 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 230000008736 traumatic injury Effects 0.000 description 1
- 229960001177 trimetazidine Drugs 0.000 description 1
- 150000007968 uric acids Chemical class 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 210000001835 viscera Anatomy 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 229940046009 vitamin E Drugs 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
- VHBFFQKBGNRLFZ-UHFFFAOYSA-N vitamin p Natural products O1C2=CC=CC=C2C(=O)C=C1C1=CC=CC=C1 VHBFFQKBGNRLFZ-UHFFFAOYSA-N 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
- 208000016261 weight loss Diseases 0.000 description 1
- 230000004580 weight loss Effects 0.000 description 1
- 230000002087 whitening effect Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/27—Asclepiadaceae (Milkweed family), e.g. hoya
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/06—Fungi, e.g. yeasts
- A61K36/07—Basidiomycota, e.g. Cryptococcus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/11—Pteridophyta or Filicophyta (ferns)
- A61K36/12—Filicopsida or Pteridopsida
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/484—Glycyrrhiza (licorice)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
- A61K36/537—Salvia (sage)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/889—Arecaceae, Palmae or Palmaceae (Palm family), e.g. date or coconut palm or palmetto
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation or decoction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/39—Complex extraction schemes, e.g. fractionation or repeated extraction steps
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Mycology (AREA)
- Biotechnology (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Botany (AREA)
- Alternative & Traditional Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Urology & Nephrology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
The invention discloses a kidney-protecting and diuretic traditional Chinese medicine preparation, and a preparation method and application thereof, wherein the kidney-protecting and diuretic traditional Chinese medicine preparation comprises the following raw materials: cortex Periplocae Radicis, caulis Akebiae, polyporus, medulla Junci, folium Pyrrosiae, pericarpium Arecae, radix Ilicis Asprellae, saviae Miltiorrhizae radix, glycyrrhrizae radix, and radix Ranunculi Ternati, wherein cortex Periplocae Radicis and Polyporus are used as principal drugs, caulis Akebiae, medulla Junci, folium Pyrrosiae, radix Ranunculi Ternati and radix Ilicis Pubescentis are used as ministerial drugs, pericarpium Arecae and Saviae Miltiorrhizae radix are used as adjuvant drugs, and Glycyrrhrizae radix is used as messenger drug, so as to achieve effects of clearing heat, promoting diuresis, protecting kidney and promoting urination, and the Chinese medicinal preparation for protecting kidney and promoting urination can be prepared into decoction for treating macula kidney formed by infectious bronchitis of chicken.
Description
Technical Field
The invention relates to the technical field of traditional Chinese medicines, in particular to a kidney-protecting and urination-promoting traditional Chinese medicine preparation and a preparation method thereof.
Background
The chicken spotted kidney is formed by the accumulation of a large amount of urate after the kidney of the chicken is developed. The pathological characteristics are that the uric acid level in blood is increased, and urate is deposited in joint capsules, joint cartilages, viscera, renal tubules and ureters. Infectious bronchitis is mostly infected in chickens, other poultry are not infected, and the infectious bronchitis belongs to kidney-type infectious bronchitis, can be pale due to kidney swelling, and kidney tubules are full of urate crystals and expanded, and are in a white wire net shape, and are commonly called as 'plaque kidneys'. Research shows that when kidney type infectious bronchitis virus infects a human body, the virus particles are distributed in groups in the cytoplasm of the kidney tubular epithelial cells, so long as the virus particles exist in the regions, the degeneration of the kidney tubular epithelial cells is induced, cavitation formation and kidney epithelial shedding are caused, mitochondria are deformed, and further, the dissolution is atrophic, and finally, the kidney failure is caused.
Currently, western medicines are mostly used for controlling kidney diseases, and medicines are used for reducing uric acid generation, accelerating uric acid excretion, eliminating kidney verification, supplementing body fluid and regulating body fluid balance, for example: urotropine is used for eliminating kidney inflammation, but urotropine can only decompose and release aldehydes in the kidney to play a role in local sterilization, and the etiology cannot be eliminated; uric acid is eliminated in the form of Na-Ca-uric acid when excreted by kidneys, and the solubility of Na-Ca-urate can be improved under acidic conditions, while the solubility of sodium bicarbonate is reduced under alkaline conditions, so that sodium bicarbonate only has the functions of alkalizing urine and improving the solubility of urate in urine, and particularly can promote the excretion of urate in early stage to a certain extent, but diarrhea, dehydration and low feed intake of organisms can be caused after a large dosage of sodium bicarbonate is used. Therefore, western medicines only can relieve symptoms, can not eliminate etiology, and have larger side effects.
Therefore, a traditional Chinese medicine preparation for protecting kidney and promoting urination is required to treat the spotted kidney formed by infectious bronchitis of chickens and the like, and can treat both symptoms and root causes when treating the disease, and treat the cause and symptoms.
Disclosure of Invention
Aiming at the prior art, the invention aims to provide a kidney-protecting and diuretic traditional Chinese medicine preparation and a preparation method and application thereof. The Chinese medicinal preparation adopts cortex Periplocae Radicis and Polyporus as principal drugs, caulis Akebiae, medulla Junci, folium Pyrrosiae, radix Clematidis Armandii and radix Ilicis Pubescentis as ministerial drugs, pericarpium Arecae and Saviae Miltiorrhizae radix as adjuvant drugs, and Glycyrrhrizae radix as conductant drugs, and has effects of clearing heat, promoting diuresis, protecting kidney and promoting urination.
In order to achieve the above purpose, the invention adopts the following technical scheme:
the invention provides a kidney-protecting and diuretic traditional Chinese medicine preparation, which comprises the following raw materials in parts by weight:
5-8 parts of cortex acanthopanacis, 2-5 parts of akebia stem, 5-8 parts of agaric, 2-5 parts of rush, 2-5 parts of pyrrosia lingua, 2-5 parts of pericarpium arecae, 2-5 parts of roughhaired holly root, 2-5 parts of red sage root, 2-5 parts of liquorice and 2-5 parts of catnip.
The dried root bark of the Wilsoniana Periploca sepium Bge of the Asclepiadaceae has the effects of inducing diuresis to alleviate edema, dispelling pathogenic wind and dampness, and strengthening tendons and bones. It is used for treating edema of lower limbs, palpitation, short breath, arthralgia due to wind-cold-dampness, soreness of waist and knees, and contains cardiac glycoside components including periplocin, etc., and volatile components including 4-methoxysalicylaldehyde, p-dimethylaminoanisole, butyl p-hydroxybenzoate, etc., and also includes glucoside.
The caulis Akebiae is dried rattan of caulis Akebiae, caulis Akebiae Trifolium Prinsepiae or caulis Aristolochiae Mollissimae of Akebiaceae, has bitter taste, cold property, and has effects of inducing diuresis, relieving swelling, clearing heat and removing pathogenic fire.
The Polyporus umbellatus is sclerotium of Polyporaceae fungus Polyporus umbellatus, has effects of relieving nature, sweet taste, and regulating kidney channel and bladder channel, has effects of promoting urination, promoting diuresis, inhibiting bacteria, resisting cancer, enhancing immunity, protecting liver, reducing liver cell HbsAg, increasing liver glycogenom accumulation, resisting radiation, etc., and has effects of promoting immunity, and contains ergosterol, biotin, protein, crude protein, soluble sugar, polysaccharide, 2-hydroxy-alpha-hydroxy-tetracosanol, sterone, etc.
The rush is dry stem pith of rush, which is a plant of the rush family of the rush, has sweet and light taste, is slightly cold, is returned to heart, lung and small intestine channels, is often used for treating vexation, insomnia, oliguria, pain and the like, and has the effects of clearing heart fire, inducing diuresis for treating stranguria, relieving sore throat, relieving pain and inducing diuresis for treating stranguria.
The pyrrosia lingua is dry leaf of pyrrosia lingua in the plant of the water dragon and the orthopaedics, namely Dan Wei pyrrosia lingua in the mountain or pyrrosia lingua with the handle, has sweet and bitter taste, enters the lung and bladder channels, has the effects of inducing diuresis to treat stranguria, clearing lung heat and relieving cough, cooling blood and stopping bleeding, contains organic acid, flavone and glycoside components thereof, and is used for treating symptoms such as stranguria due to heat, difficult urination, dribbling pain and the like.
The areca peel is the dried pericarp of areca catechu of palmaceae, has pungent and slightly warm taste, enters spleen, stomach, large intestine and small intestine channels, has the effects of promoting qi circulation, relieving middle energizer, promoting water circulation and reducing edema, is commonly used for damp obstruction, qi stagnation, edema, fullness, difficult urination and the like, and mainly contains effective components such as alkaloids, tannins and the like.
The roughhaired holly root is the root of roughhaired holly leaf of the ilex plant of the ilex family, bitter and sweet, cool, has the effects of clearing heat and detoxicating, promoting the production of body fluid to quench thirst and dissipating blood stasis, and is commonly used for common cold, headache, dizziness, pyretic polydipsia, sunstroke qi, heat diarrhea, pulmonary abscess, pertussis, sore throat, hemorrhoids and hematoma, gonorrhea, furuncle and pyogenic infections and traumatic injury.
The red sage root is dried rhizome of red sage root of Labiatae, has bitter taste, slight cold, heart and lung channel returning, can dispel heat and clear slight cold energy, has the functions of activating blood circulation to dissipate blood stasis to relieve pain, refreshing and cooling blood to relieve restlessness and pain, mainly treats blood stasis, blood heat and heat disturbing heart spirit symptoms, treats heat toxin sore pain and swelling and pain, contains protocatechualdehyde, protocatechuic acid, lactic acid, vitamin E and the like, and has the functions of activating blood circulation to remove blood stasis, dredging channels to relieve pain, clearing heart fire and relieving restlessness and cooling blood to relieve pain.
The Glycyrrhrizae radix is dry root and rhizome of Glycyrrhrizae radix of Leguminosae, and Glycyrrhiza glabra, has sweet taste, and can restore heart, lung, spleen and stomach channels, and has effects of invigorating qi, invigorating middle warmer, relieving spasm and pain, relieving drug property, eliminating phlegm, relieving cough, removing toxic substance, and contains Sanku soap class and flavonoid.
The Dai nationality of Xishuangbanna calls the Maotai herb as the beautiful tooth path, is herb of herba Clerodendranthi Spicati of Clerodendranthus of Labiatae, has sweet and slightly bitter taste, and has effects of heat, promoting urination, and removing calculus.
Polyporus has effects of promoting diuresis, removing dampness and clearing heat, and is added with Pi Lishui for detumescence, and is used as monarch drug; akebia quinata, rush and Dan Wei induce diuresis to treat stranguria, radix clerodendri catenulatus has the effects of clearing heat and removing dampness, discharging Dan Lishui, and roughhaired holly root has the effects of clearing heat and promoting the production of body fluid, and activating blood and detoxicating, and is taken as ministerial drug; the pericarpium arecae is used as an adjuvant drug for promoting qi circulation, relieving the middle energizer, inducing diuresis to alleviate edema, nourishing blood, promoting blood circulation, removing blood stasis and relieving pain; licorice root, radix Glycyrrhizae regulates the action of other drugs and acts as a guiding drug.
The invention provides a preparation method of a kidney-protecting and diuretic traditional Chinese medicine preparation, which comprises the following steps:
(1) Mixing cortex Periplocae Radicis, caulis Akebiae, polyporus, medulla Junci, folium Pyrrosiae, pericarpium Arecae, radix Ilicis Asprellae, saviae Miltiorrhizae radix, glycyrrhrizae radix, and radix Ranunculi Ternati to obtain a mixture, decocting the mixture with water for one time, and filtering to obtain residue and a filtrate;
(2) Adding water into the residues for secondary decoction, and filtering to obtain secondary filtrate;
(3) Mixing the primary filtrate and the secondary filtrate, and concentrating to obtain the kidney-protecting and diuretic Chinese medicinal preparation.
Preferably, in the step (1), the water addition amount is 8-10 times of the mass of the mixture, and the decoction time is 25-35min.
Preferably, in the step (2), the water addition amount is 4-6 times of the mass of the mixture, and the decoction time is 20-30min.
Preferably, in the step (3), the concentration of the crude drug is 0.8-1.2g/mL.
In a third aspect, the invention provides an application of a traditional Chinese medicine preparation in preparing a kidney-protecting and diuretic traditional Chinese medicine preparation.
The invention provides a kidney-protecting and diuretic traditional Chinese medicine preparation, which comprises a kidney-protecting and diuretic traditional Chinese medicine preparation and pharmaceutically acceptable auxiliary materials.
Preferably, the kidney protecting and diuretic Chinese medicinal preparation is one of a tablet, a capsule, a granule, a mixture or a pill.
The invention has the beneficial effects that:
The invention adopts Chinese herbal medicines to effectively treat the spotted kidney formed by infectious bronchitis and the like of chickens, and obtains a traditional Chinese medicine preparation for clearing heat and promoting diuresis, protecting kidney and promoting urination through reasonable compatibility, specifically, polyporus has the effects of promoting diuresis and removing dampness and heat, and is fragrant and has Pi Lishui for detumescence, and the traditional Chinese medicine preparation is taken as a main medicine; akebia quinata, rush and Dan Wei induce diuresis to treat stranguria, radix clerodendri catenulatae for clearing heat and removing dampness and discharging Dan Lishui, and roughhaired holly root for clearing heat and promoting the production of body fluid and activating blood and detoxicating are ministerial drugs; the pericarpium arecae is used as an adjuvant drug for promoting qi circulation, relieving the middle energizer, inducing diuresis to alleviate edema, nourishing blood, promoting blood circulation, removing blood stasis and relieving pain; licorice root, radix Glycyrrhizae regulates the action of other drugs and acts as a guiding drug.
Detailed Description
It should be noted that the following detailed description is illustrative and is intended to provide further explanation of the application. Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this application belongs.
As described in the background art, the spotted kidney of the chicken is mainly caused by infectious bronchitis, kidney failure can be caused after the body is infected by kidney-type infectious bronchitis virus, western medicines are mostly adopted at present for treating the spotted kidney, but the western medicines only can relieve symptoms, can not eliminate etiology and have great side effects.
Based on the above, aiming at the causes of the chicken's spotted kidney caused by infectious bronchitis and poor effect of western medicines for treating the spotted kidney, the invention develops a traditional Chinese medicine preparation with kidney preservation, diuresis, heat clearing and diuresis promoting functions as a traditional Chinese veterinary medicine for treating the chicken's spotted kidney by using the modern analysis theory, technology and method as guidance by taking the traditional Chinese veterinary medicine theory and the medicine principle.
In view of the concept that Chinese veterinary medicine theory pays attention to the whole body, when the Chinese veterinary medicine is a compound preparation, the chemical components of the Chinese veterinary medicine are diversified, the content changes greatly, and the Chinese veterinary medicine can be mutually influenced to generate a plurality of stable or sub-stable complex compounds. The invention screens from related books of traditional Chinese veterinary medicine raw materials such as the pharmacopoeia of the people's republic of China (2020 edition), the common Chinese herbal medicine handbook (people health publishing company) and the like, combines a large number of experimental verification, and obtains the traditional Chinese medicine preparation which takes cortex acanthopanacis and Polyporus as principal drugs, takes akebia stem, rush, pyrrosia lingua, radix clematidis and roughhaired holly root as ministerial drugs, takes pericarpium arecae and radix salviae miltiorrhizae as ministerial drugs, takes liquorice as ministerial drugs, and takes the cortex acanthopanacis as the ministerial drugs, wherein the cortex acanthopanacis has the effects of promoting diuresis, removing dampness by diuresis, taking the Polyporus, promoting diuresis by the polyporus, taking the akebia stem, the rush herb and the pyrrosia lita herb, removing dampness by clearing heat and removing the evil, expelling Dan Lishui, clearing heat by the roughhaired holly root, promoting blood circulation and removing toxin, promoting qi and expelling the middle energizer of the stomach, and promoting blood circulation by dissolving stasis and relieving pain, and the liquorice can harmonizing the principal drugs by the principal drugs, the ministerial drugs, the invention has the reasonable compatibility of the principal drugs, the assistant drugs and the drug.
The invention provides a formula of a traditional Chinese medicine preparation in a specific embodiment, which comprises the following specific components: 5-8 parts of cortex acanthopanacis, 2-5 parts of akebia stem, 5-8 parts of agaric, 2-5 parts of rush, 2-5 parts of pyrrosia lingua, 2-5 parts of pericarpium arecae, 2-5 parts of roughhaired holly root, 2-5 parts of red sage root, 2-5 parts of liquorice and 2-5 parts of catnip.
In another embodiment of the present invention, a method for preparing a Chinese medicinal preparation is provided, comprising the steps of:
(1) Mixing cortex Periplocae Radicis, caulis Akebiae, polyporus, medulla Junci, folium Pyrrosiae, pericarpium Arecae, radix Ilicis Asprellae, saviae Miltiorrhizae radix, glycyrrhrizae radix, and radix Ranunculi Ternati to obtain mixture, adding water into the mixture, decocting for 25-35min with water amount of 8-10 times of the mass of the mixture, filtering to obtain filter residue and primary filtrate
(2) Adding water into the filter residue for secondary decoction, wherein the water amount is 4-6 times of the mass of the mixture, the secondary decoction time is 20-30min, and filtering to obtain secondary filtrate;
(3) Mixing the primary filtrate and the secondary filtrate, and concentrating to obtain Chinese medicinal preparation with crude drug concentration of 0.8-1.2 g/mL.
The crude drug concentration is the total mass of cortex Periplocae Radicis, caulis Akebiae, polyporus, medulla Junci, folium Pyrrosiae, pericarpium Arecae, radix Ilicis Asprellae, saviae Miltiorrhizae radix, glycyrrhrizae radix and radix Ranunculi Ternati, and the volume ratio of the concentrated filtrate.
In order to enable those skilled in the art to more clearly understand the technical scheme of the present application, the technical scheme of the present application will be described in detail with reference to specific embodiments.
The test materials used in the examples of the present invention are all conventional in the art and are commercially available.
Example 1: preparation of kidney-protecting diuretic traditional Chinese medicine
(1) Mixing cortex Periplocae Radicis, caulis Akebiae, polyporus, medulla Junci, folium Pyrrosiae, pericarpium Arecae, radix Ilicis Asprellae, saviae Miltiorrhizae radix, glycyrrhrizae radix, radix Ranunculi Ternati at a mass ratio of 7:3:6:3:3:3:3:3:3:3 to obtain a mixture, adding water into the mixture, decocting for one time with water content 9 times of the mass of the mixture, decocting for 30min, and filtering to obtain filter residue and primary filtrate;
(2) Adding water into the filter residue for secondary decoction, wherein the water amount is 5 times of the mass of the mixture, the secondary decoction time is 25min, and filtering to obtain secondary filtrate;
(3) Mixing the primary filtrate and the secondary filtrate, concentrating to obtain the traditional Chinese medicine preparation with crude drug concentration of 1g/mL, namely the kidney protecting and diuretic traditional Chinese medicine preparation.
Example 2: preparation of kidney-protecting and urination-promoting traditional Chinese medicine preparation
(1) Mixing cortex Periplocae Radicis, caulis Akebiae, polyporus, medulla Junci, folium Pyrrosiae, pericarpium Arecae, radix Ilicis Asprellae, saviae Miltiorrhizae radix, glycyrrhrizae radix, radix Ranunculi Ternati at a mass ratio of 5:2:5:2:2:2:2:2:2:2:2 to obtain a mixture, adding water into the mixture, decocting for one time with water content of 8 times of the mass of the mixture, decocting for 25min, and filtering to obtain filter residue and primary filtrate;
(2) Adding water into the filter residue for secondary decoction, wherein the water amount is 4 times of the mass of the mixture, the secondary decoction time is 20min, and filtering to obtain secondary filtrate;
(3) Mixing the primary filtrate and the secondary filtrate, concentrating to obtain the traditional Chinese medicine preparation with the crude drug concentration of 0.8g/mL, namely the kidney protecting and diuretic traditional Chinese medicine preparation.
Example 3: preparation of kidney-protecting and urination-promoting traditional Chinese medicine preparation
(1) Mixing cortex Periplocae Radicis, caulis Akebiae, polyporus, medulla Junci, folium Pyrrosiae, pericarpium Arecae, radix Ilicis Asprellae, saviae Miltiorrhizae radix, glycyrrhrizae radix, radix Ranunculi Ternati at a mass ratio of 8:5:8:5:5:5:5:5:5:5 to obtain a mixture, adding water into the mixture, decocting for one time with water content 10 times of the mass of the mixture, decocting for 35min, and filtering to obtain filter residue and primary filtrate;
(2) Adding water into the filter residue for secondary decoction, wherein the water amount is 6 times of the mass of the mixture, the secondary decoction time is 30min, and filtering to obtain secondary filtrate;
(3) Mixing the primary filtrate and the secondary filtrate, concentrating to obtain the traditional Chinese medicine preparation with crude drug concentration of 1.2g/mL, namely the kidney protecting and diuretic traditional Chinese medicine preparation.
Comparative example 1: preparation of kidney-protecting and urination-promoting traditional Chinese medicine preparation
(1) Mixing cortex Periplocae Radicis and Polyporus in a mass ratio of 7:6 to obtain a mixture, adding water into the mixture, decocting for 30min with water amount 9 times of the mixture mass, and filtering to obtain residue and primary filtrate;
(2) Adding water into the filter residue for secondary decoction, wherein the water amount is 5 times of the mass of the mixture, the secondary decoction time is 25min, and filtering to obtain secondary filtrate;
(3) Mixing the primary filtrate and the secondary filtrate, concentrating to obtain the traditional Chinese medicine preparation with crude drug concentration of 1g/mL, namely the kidney protecting and diuretic traditional Chinese medicine preparation.
Comparative example 2: preparation of kidney-protecting and urination-promoting traditional Chinese medicine preparation
(1) Mixing caulis Akebiae, medulla Junci, folium Pyrrosiae, radix Ilicis Asprellae and radix Ranunculi Ternati at a ratio of 3:3:3:3 to obtain a mixture, adding water into the mixture, decocting for 30min for 9 times of the mixture, and filtering to obtain residue and primary filtrate;
(2) Adding water into the filter residue for secondary decoction, wherein the water amount is 5 times of the mass of the mixture, the secondary decoction time is 25min, and filtering to obtain secondary filtrate;
(3) Mixing the primary filtrate and the secondary filtrate, concentrating to obtain the traditional Chinese medicine preparation with crude drug concentration of 1g/mL, namely the kidney protecting and diuretic traditional Chinese medicine preparation.
Comparative example 3: preparation of kidney-protecting and urination-promoting traditional Chinese medicine preparation
(1) Mixing pericarpium Arecae, saviae Miltiorrhizae radix, and Glycyrrhrizae radix at a mass ratio of 3:3:3 to obtain a mixture, adding water into the mixture, decocting for 30min with water amount of 9 times of the mixture, and filtering to obtain residue and primary filtrate;
(2) Adding water into the filter residue for secondary decoction, wherein the water amount is 5 times of the mass of the mixture, the secondary decoction time is 25min, and filtering to obtain secondary filtrate;
(3) Mixing the primary filtrate and the secondary filtrate, concentrating to obtain the traditional Chinese medicine preparation with crude drug concentration of 1g/mL, namely the kidney protecting and diuretic traditional Chinese medicine preparation.
Test example 1: animal experiment
This experimental example references the experimental study of the effects of trimetazidine on renal fibrosis and apoptosis in rats with chronic renal failure models (Zhou Jinjin Xu Guyun, J.Ne.3, 3 rd edition, volume 23, CJITWN, march 2022, vol.23, no.3, incorporated by reference in Kidney J.Patent disease 2022, china).
The specific test steps are as follows:
(1) 60 male clean SD rats with the weight of 200-260g are selected, purchased from Jinan Pengyue laboratory animal breeding limited company, are placed in an environment with the temperature of 20-24 ℃ and the humidity of 40-65% for three days and then are subjected to test, and the rats can eat water freely during the feeding period.
(2) 10 Rats are randomly selected as a control group, and the rest rats are fed with adenine feed 21d to construct a chronic renal failure model rat model, wherein the adenine feed consists of adenine and common feed, the mass fraction of adenine in the adenine feed is 5%, and the common feed is 'experimental mouse quasi feed' purchased from Jinan Pengyue laboratory animal breeding Co.
After the rats have symptoms of weight loss, activity reduction, reaction retardation, wet and cold limbs, curled dorsum arch, mao Song stool dilution and the like, after 2 rats are randomly selected for anesthesia, abdominal aorta is used for blood collection, a biochemical analyzer is used for detecting the contents of serum creatinine (Scr) and urea nitrogen (BUN), hematoxylin-eosin (HE) staining is used for observing pathological changes of kidney tissues, and modeling is judged to be successful. During the molding period, rats in the control group were given normal feed; after successful molding, each group of rats was given normal feed.
(3) The rats after successful modeling are divided into a model group, a test group 1, a test group 2, a test group 3 and a test group 4 at random, wherein,
Rats in test group 1 were perfused daily with the kidney-protecting diuretic traditional Chinese medicine preparation prepared in example 1;
rats in test group 2 were perfused daily with the kidney-protecting diuretic traditional Chinese medicine preparation prepared in comparative example 1;
Rats in test group 3 were perfused daily with the kidney-protecting diuretic traditional Chinese medicine preparation prepared in comparative example 2;
Rats in test group 4 were perfused daily with the kidney-protecting diuretic traditional Chinese medicine preparation prepared in comparative example 3.
The traditional Chinese medicine preparation has the stomach filling amount of 3mL/kg (rat weight), and is filled once per day in a fixed time period, and the control group and the model group are replaced by the same amount of physiological saline.
(4) MRNA expression was detected by fluorescent quantitative PCR.
The specific method comprises the following steps: total RNA is extracted from kidney tissues of each group of rats, cDNA template chains are synthesized through reverse transcription reaction, SYBRGreen fluorescent dye is added for qRT detection, alpha smooth muscle myoprotein (alpha-SMA), transforming growth factor beta 1（TGF-β1 and type I collagen (collagen I) are calculated by taking GADPH as an internal reference, and the results are shown in a table 1, wherein the sequences of the primers are as follows:
GADPH
Upstream 5'-CAGTCAGCCGCATCTTCTTT-3'
Downstream 5'-GACCAAATCCGTTGACTCCG-3'
α-SMA
Upstream 5'-CTTCTATAACGAGCTTCGC-3'
Downstream 5'-TCCAGAGTCCAGCACAAT-3'
TGF-β1
Upstream 5'-AGGCGGTGCTCGCTTTGT-3'
Downstream 5'-GATTGCGTTGTTGCGGTCC-3'
collagen Ⅰ
Upstream 5'-ACTCAGCCCTCTGTGCCT-3'
Downstream 5'-CCTTCGCTTCCATACTCG-3'
Table 1 quantitative analysis results of alpha smooth muscle actin, transforming growth factor beta 1 and type I collagen in each group
Rat modeling is carried out by using adenine, and chloride 2, 8-dihydroxyadenine in adenine is deposited on the renal tubule in a large amount in an insoluble crystal form, so that the renal tubule is partially expanded, partially denatured and necrotized, interstitial lymph and mononuclear cells infiltrate, a large amount of granulomatous hyperplasia nodules are formed around the 2, 8-dihydroxyadenine crystal in late stage of pathological change, and renal interstitial mass is widely fibrosed.
Alpha smooth muscle actin (alpha-SMA) is an important marker for the phenotypic conversion of tubular epithelial cells-myofibroblasts, and alpha-SMA is a marker for renal interstitial cells with a small expression level in normal renal interstitial. Transforming growth factor beta 1 is a key factor for causing the phenotype transformation of tubular epithelial cells-myofibroblasts, TGF-beta 1 promotes the differentiation of fibroblasts and tubular epithelial cells and expresses alpha-SMA to cause tubular interstitial fibrosis, is an important cytokine for promoting the development of renal failure, and has a small expression level in normal renal interstitial. Type I collagen (collagen I) is weakly expressed in the normal kidney proximal and distal stroma, and is not expressed in intravascular blood cells and epithelium; there is no expression where renal interstitial fibrosis is complete, nor in the extremely distended tubule epithelium, but more pronounced expression in denatured epithelial cells.
As can be seen from Table 1, the control group is a normal rat, the model group is a rat with chronic renal failure with successful molding, the kidney-protecting and diuretic traditional Chinese medicine preparation of the invention is used for lavaging the rat with successful molding, compared with the model group, the expression amounts of alpha smooth muscle myoprotein, transforming growth factor beta 1 and type I collagen are obviously reduced, and are lower than the expression amounts of alpha smooth muscle myoprotein, transforming growth factor beta 1 and type I collagen of the rat in the test group 2-4, so that the kidney-protecting and diuretic traditional Chinese medicine preparation of the invention can obviously improve renal interstitial fibrosis and is effective for chronic renal failure.
Test example 2:
In Shandong Taian-cultivation base, 3000 sea-blue brown laying hens with 28 days of age have mental depression and anorexia, discharge off-white thin feces or white pasty feces, sometimes take the form of water-sample diarrhea, seriously lose water, and dissect and detect double kidney swelling and pallidum, and kidney tubules gather uric acid salt to lead the kidney to take the shape of betel nut-like flower spots, namely the spotted kidney. The ureters on both sides become obviously dilated due to the deposition of the urate, thickening and whitening. In chronic cases, kidneys fade and PCR detects infectious bronchitis infection.
Through negotiating with breeders to purchase 250 sick chickens, isolating 50 sick sea-blue brown laying hens as a control group, randomly selecting 200 sick sea-blue brown laying hens from the rest of sick sea-blue brown laying hens to be equally divided into 4 groups, namely a test group 1, a test group 2, a test group 3 and a test group 4 respectively,
The traditional Chinese medicine preparation for protecting kidney and promoting urination, which is prepared in example 1, is prepared by the stomach of the sick sea blue brown layer chicken of the test group 1;
the traditional Chinese medicine preparation for protecting kidney and promoting urination, which is prepared in comparative example 1, is prepared by the sick sea blue brown laying hen of test group 2 by lavaging every day;
The traditional Chinese medicine preparation for protecting kidney and promoting urination, which is prepared in comparative example 2, is prepared by the sick sea blue brown laying hen of test group 3 by lavaging every day;
the traditional Chinese medicine preparation for protecting kidney and promoting urination, which is prepared in comparative example 3, is prepared by the stomach of the sick sea blue brown laying hen of the test group 4;
The traditional Chinese medicine preparation for preventing the diseased sea-blue brown laying hen from being irrigated with stomach and protecting kidney and promoting urination in the control group, and the traditional Chinese medicine preparation for preventing the diseased sea-blue brown laying hen from being irrigated with stomach and promoting urination in the test group 1-4 is 0.5mL/kg (the weight of the diseased sea-blue brown laying hen), and the traditional Chinese medicine preparation is irrigated with stomach continuously for 7 days, and the traditional Chinese medicine preparation is irrigated with stomach 1 time at eight early points every day.
In the test process, the breeding base is thoroughly disinfected at fixed time every day, the feeding management and the feeding condition of each group of chickens are consistent, the clinical symptoms of each group of chickens are observed and recorded every day from the first day after administration, the conditions of mental state, appetite, respiratory calm, death and the like are mainly recorded, the continuous observation is carried out for 15 days, and the clinical curative effect and average weight gain are counted, and the results are shown in Table 2. Wherein,
1. The average weight gain calculation method comprises the following steps: the weight of each chicken is weighed before the experiment, the average value is taken, the average value is the average weight m 1 before the experiment, the weight of each surviving chicken is respectively weighed again after the experiment is finished, the average value is taken as the average weight m 2 after the experiment is finished, the average weight difference before and after the experiment is the average weight gain delta m, and the weighing time is half an hour before feeding in the morning.
2. Clinical efficacy decision criteria:
The effect is shown: after the test, the chickens are only psychoactive and have no influence;
Invalidation: the disease symptoms of the chickens were not significantly improved after the test, and still exhibited at least one of the following disease symptoms.
The onset symptoms include: depression, coarse and disordered feathers, drooping wings, reduced or abolished appetite, dyspnea, roasts, coughing, open mouth breathing, sneeze, diarrhea, and white urate thin feces, the chicken dies, and the split examination shows plaque nephrosis.
Effective rate = [ effective number/50 ] ×100%
TABLE 2 average weight gain and effective rate
Infectious bronchitis of chickens is an acute and highly infectious respiratory disease, and the sick chicken group has slight respiratory symptoms in the early 2-3 days, then undergoes an acute kidney disease stage, and is subjected to a section examination, so that the kidney is swollen, faded, pale and takes the shape of red-white spots (namely, spotted kidneys). As can be seen from Table 2, the average weight of the sick chickens can be increased by 219g by adopting the traditional Chinese medicine preparation for protecting the kidney and promoting urination for the spotted kidneys formed by infectious bronchitis of chickens, and meanwhile, the effective rate of the traditional Chinese medicine preparation for protecting the kidneys and promoting urination can be obviously improved to 90.0% which is far higher than the average weight increase and the effective rate of the sick chickens after monarch drugs, ministerial drugs, adjuvant drugs and post-administration drugs are respectively adopted in test groups 2-4.
The above description is only of the preferred embodiments of the present application and is not intended to limit the present application, but various modifications and variations can be made to the present application by those skilled in the art. Any modification, equivalent replacement, improvement, etc. made within the spirit and principle of the present application should be included in the protection scope of the present application.
Claims (8)
1. The traditional Chinese medicine preparation for protecting kidney and promoting urination is characterized by comprising the following raw materials in parts by weight:
5-8 parts of cortex acanthopanacis, 2-5 parts of akebia stem, 5-8 parts of agaric, 2-5 parts of rush, 2-5 parts of pyrrosia lingua, 2-5 parts of pericarpium arecae, 2-5 parts of roughhaired holly root, 2-5 parts of red sage root, 2-5 parts of liquorice and 2-5 parts of catnip.
2. The preparation method of the kidney-protecting diuretic traditional Chinese medicine preparation as claimed in claim 1, which is characterized by comprising the following steps:
(1) Mixing cortex Periplocae Radicis, caulis Akebiae, polyporus, medulla Junci, folium Pyrrosiae, pericarpium Arecae, radix Ilicis Asprellae, saviae Miltiorrhizae radix, glycyrrhrizae radix, and radix Ranunculi Ternati to obtain a mixture, adding water into the mixture, decocting for one time, and filtering to obtain residue and primary filtrate;
(2) Adding water into the residues for secondary decoction, and filtering to obtain secondary filtrate;
(3) Mixing the primary filtrate and the secondary filtrate, and concentrating to obtain the kidney-protecting and diuretic Chinese medicinal preparation.
3. The method for preparing a kidney-protecting diuretic Chinese medicinal preparation according to claim 2, wherein in the step (1), the water addition amount is 8-10 times of the mass of the mixture, and the decoction time is 25-35min.
4. The method for preparing a kidney-protecting diuretic Chinese medicinal preparation according to claim 2, wherein in the step (2), the water addition amount is 4-6 times of the mass of the mixture, and the decoction time is 20-30min.
5. The method for preparing a kidney-protecting diuretic Chinese medicinal preparation according to claim 2, wherein the concentration of crude drugs is 0.8-1.2g/mL.
6. The use of the Chinese medicinal preparation of claim 1 in preparing kidney protecting and diuretic Chinese medicinal preparation.
7. The kidney-protecting diuretic traditional Chinese medicine preparation is characterized by comprising the kidney-protecting diuretic traditional Chinese medicine preparation and pharmaceutically acceptable auxiliary materials according to claim 1.
8. The kidney-protecting diuretic traditional Chinese medicine preparation according to claim 7, wherein the kidney-protecting diuretic traditional Chinese medicine preparation is one of a tablet, a capsule, a granule, a mixture or a pill.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202310900192.0A CN116832105B (en) | 2023-07-21 | 2023-07-21 | Traditional Chinese medicine preparation for protecting kidney and promoting urination and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202310900192.0A CN116832105B (en) | 2023-07-21 | 2023-07-21 | Traditional Chinese medicine preparation for protecting kidney and promoting urination and preparation method thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN116832105A CN116832105A (en) | 2023-10-03 |
| CN116832105B true CN116832105B (en) | 2024-05-14 |
Family
ID=88174261
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202310900192.0A Active CN116832105B (en) | 2023-07-21 | 2023-07-21 | Traditional Chinese medicine preparation for protecting kidney and promoting urination and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN116832105B (en) |
Citations (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR100770634B1 (en) * | 2006-08-17 | 2007-10-26 | 박용기 | Pharmaceutical composition for preventing and treatmenting from disease related to renal failure |
| CN101940646A (en) * | 2010-09-07 | 2011-01-12 | 陈鹏举 | Chinese medicine composition for preventing and curing nephropathogenic infectious bronchitis |
| CN102205061A (en) * | 2011-05-10 | 2011-10-05 | 蒋保珍 | Medicament for treating nephropathogenic infectious bronchitis in chicken and preparation method thereof |
| WO2012050397A2 (en) * | 2010-10-14 | 2012-04-19 | 주식회사 한국전통의학연구소 | Pharmaceutical composition including herbal medicine extract for preventing or treating kidney cancer |
| CN102526366A (en) * | 2012-02-21 | 2012-07-04 | 简福川 | Chinese medicine for treating nephritis |
| CN105327180A (en) * | 2015-11-25 | 2016-02-17 | 董芳 | Traditional Chinese medicine preparation for treating kidney stones |
| CN105687538A (en) * | 2016-03-11 | 2016-06-22 | 庄甲菁 | Drug for treating anterior pituitary hypofunction |
| CN111686185A (en) * | 2020-07-14 | 2020-09-22 | 王玉梅 | Traditional Chinese medicine composition for treating dilated cardiomyopathy and preparation method thereof |
-
2023
- 2023-07-21 CN CN202310900192.0A patent/CN116832105B/en active Active
Patent Citations (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR100770634B1 (en) * | 2006-08-17 | 2007-10-26 | 박용기 | Pharmaceutical composition for preventing and treatmenting from disease related to renal failure |
| CN101940646A (en) * | 2010-09-07 | 2011-01-12 | 陈鹏举 | Chinese medicine composition for preventing and curing nephropathogenic infectious bronchitis |
| WO2012050397A2 (en) * | 2010-10-14 | 2012-04-19 | 주식회사 한국전통의학연구소 | Pharmaceutical composition including herbal medicine extract for preventing or treating kidney cancer |
| CN102205061A (en) * | 2011-05-10 | 2011-10-05 | 蒋保珍 | Medicament for treating nephropathogenic infectious bronchitis in chicken and preparation method thereof |
| CN102526366A (en) * | 2012-02-21 | 2012-07-04 | 简福川 | Chinese medicine for treating nephritis |
| CN105327180A (en) * | 2015-11-25 | 2016-02-17 | 董芳 | Traditional Chinese medicine preparation for treating kidney stones |
| CN105687538A (en) * | 2016-03-11 | 2016-06-22 | 庄甲菁 | Drug for treating anterior pituitary hypofunction |
| CN111686185A (en) * | 2020-07-14 | 2020-09-22 | 王玉梅 | Traditional Chinese medicine composition for treating dilated cardiomyopathy and preparation method thereof |
Non-Patent Citations (3)
| Title |
|---|
| Ying-Yong Zhao.Traditionaluses,phytochemistry,pharmacology,pharmacokineticsandqualitycontrolof Polyporusumbellatus (Pers.) Fries:Areview.Journal ofEthnopharmacology.2013,第149卷35-48. * |
| 商品鸡"花斑肾"成因及防治;田琴;山东畜牧兽医;20101231(第10期);56-57 * |
| 治疗鸡"花斑肾"病的体会;孙展和;中国禽业导刊;20081231;第25卷(第11期);39 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN116832105A (en) | 2023-10-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR101787432B1 (en) | Method for manufacturing oriental medicine composition which improves menorrhagia and dysmenorrhea comprising fermented velvet antler and yeast hydrolysate | |
| CN102755505B (en) | Traditional Chinese medicinal herb mixture for preventing and treating new castle disease and production technology | |
| CN103690919B (en) | Medicine being used for the treatment of piglet iron-deficiency anemia and preparation method thereof | |
| CN104187172B (en) | Functional feed for treating enterogastritis diseases of turtles and preparation method of functional feed | |
| CN108853217A (en) | A kind of pharmaceutical composition and its application for treating chicken Mycoplasma synoviae | |
| CN104306659B (en) | A kind of Chinese medicine composition for treating diabetes B | |
| CN102106941A (en) | Traditional Chinese medicine preparation for treating piles and preparation method of traditional Chinese medicine preparation | |
| CN107158223A (en) | For clearing heat and detoxicating Chinese medicine preparation with anti-inflammatory and preparation method thereof | |
| CN103494927B (en) | Traditional Chinese medicine composition for treating chicken respiratory disease and preparation method thereof | |
| CN116832105B (en) | Traditional Chinese medicine preparation for protecting kidney and promoting urination and preparation method thereof | |
| CN102698158A (en) | Traditional Chinese medicine for preventing and treating infectious bronchitis, preparation method thereof and feed | |
| CN113491743B (en) | Pharmaceutical composition for preventing and treating gout of birds and preparation method and application thereof | |
| CN105497723A (en) | Traditional Chinese medicine preparation for treating bacterial pneumonia and preparation method thereof | |
| CN105194225A (en) | Traditional Chinese medicine for treatment of children iron deficiency anemia | |
| CN104208358A (en) | Traditional Chinese medicine for treating renal calculi | |
| CN103860977B (en) | A kind of pharmaceutical composition for the treatment of dermatitis | |
| CN106728010A (en) | A kind of pharmaceutical composition and its preparation technology for livestock and poultry cough and asthma | |
| CN105535502A (en) | Traditional Chinese medicine preparation for treating adult periodontitis and preparation method of traditional Chinese medicine preparation | |
| CN105663299A (en) | Traditional Chinese medicine preparation for treating stable angina pectoris and preparing method of traditional Chinese medicine preparation | |
| CN104547462B (en) | A kind of Chinese medicine composition to relax bowel and preparation method thereof | |
| CN104906400A (en) | Traditional Chinese medicine for treating acute cerebral ischemic stroke | |
| CN104623068A (en) | Medicine for treating infantile fever and convulsion and preparation method of medicine | |
| CN117731709B (en) | Medicine for treating prostatitis and prostatic hyperplasia and preparation method and application thereof | |
| CN104208168B (en) | A kind of for compound traditional Chinese medicine composite treating poultry respiratory infection and preparation method thereof | |
| CN105535802A (en) | Traditional Chinese medicine preparation for treating habitual abortion and preparation method of traditional Chinese medicine preparation |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |